Objective: To investigate the effects of budesonide on blood gas and inflammation indexes in patients with chronic obstructive pulmonary disease (COPD) during remission. Methods: Fifty-one patients with COPD in remission, admitted to Zhongshan Hospital of Dalian University from July 2021 to December 2022, were selected and divided into two groups based on a randomized numerical table method. The control group (25 cases) received budesonide formoterol treatment, while the observation group (26 cases) received budesonide geforce treatment. Various indexes, including clinical efficacy, blood gas indexes, inflammation indexes, St. George’s Respiratory Questionnaire (SGRQ) scores, Chronic Obstructive Pulmonary Disease Assessment Test (CAT) scores, and 6-minute Walking Distance Test (6MWD) results, were compared between the two groups. Results: After 21 days of treatment, the total clinical effectiveness rate of the observation group was higher than that of the control group, with a statistically significant difference (P < 0.05). Post-treatment, the PaO₂ level and pH value in both groups were higher, and the PaCO₂ level was lower compared to pre-treatment levels. The observation group showed better improvements in these indicators than the control group, with statistically significant differences (P < 0.05). SGRQ and CAT scores for both groups were lower post-treatment, with the observation group scoring lower than the control group. Additionally, the 6MWD results were farther for both groups post-treatment, with the observation group achieving greater distances than the control group, with statistically significant differences (P < 0.05). Conclusion: Budesonide can effectively improve blood gas indexes in patients with COPD in remission, alleviate related clinical symptoms, reduce inflammatory responses, and promote patient recovery. The treatment efficacy is significant.